HK1232147A1 - 用於治療纖維化的賽尼克韋羅 - Google Patents
用於治療纖維化的賽尼克韋羅Info
- Publication number
- HK1232147A1 HK1232147A1 HK17105882.1A HK17105882A HK1232147A1 HK 1232147 A1 HK1232147 A1 HK 1232147A1 HK 17105882 A HK17105882 A HK 17105882A HK 1232147 A1 HK1232147 A1 HK 1232147A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cenicriviroc
- fibrosis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968829P | 2014-03-21 | 2014-03-21 | |
US201462024713P | 2014-07-15 | 2014-07-15 | |
US201562114304P | 2015-02-10 | 2015-02-10 | |
PCT/US2015/021828 WO2015143367A2 (en) | 2014-03-21 | 2015-03-20 | Cenicriviroc for the treatment of fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1232147A1 true HK1232147A1 (zh) | 2018-01-05 |
Family
ID=54145485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17105882.1A HK1232147A1 (zh) | 2014-03-21 | 2017-06-14 | 用於治療纖維化的賽尼克韋羅 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20170239262A1 (zh) |
EP (2) | EP3119401A4 (zh) |
JP (1) | JP6556825B2 (zh) |
KR (1) | KR20160132489A (zh) |
CN (1) | CN106488769A (zh) |
AU (2) | AU2015230986A1 (zh) |
BR (1) | BR112016021682A2 (zh) |
CA (1) | CA2941411A1 (zh) |
CL (1) | CL2016002372A1 (zh) |
HK (1) | HK1232147A1 (zh) |
IL (1) | IL247515A0 (zh) |
MA (1) | MA39748A (zh) |
MX (1) | MX2016012262A (zh) |
RU (2) | RU2724339C2 (zh) |
SG (2) | SG11201607859SA (zh) |
WO (1) | WO2015143367A2 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR034985A1 (es) | 2001-08-08 | 2004-03-24 | Takeda Chemical Industries Ltd | Compuesto biciclico; produccion y uso del mismo |
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
SG10201801654RA (en) | 2014-05-28 | 2018-04-27 | Childrens Hospital Med Ct | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
SG10201902137PA (en) * | 2014-09-12 | 2019-04-29 | Tobira Therapeutics Inc | Cenicriviroc combination therapy for the treatment of fibrosis |
EP3207123A1 (en) | 2014-10-17 | 2017-08-23 | Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
EP3237424A4 (en) | 2014-12-23 | 2018-07-04 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
BR112018005163A2 (pt) * | 2015-09-16 | 2018-10-09 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
WO2017103001A2 (en) * | 2015-12-16 | 2017-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections |
FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
WO2017192997A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
CA3028151A1 (en) | 2016-06-21 | 2017-12-28 | Tobira Therapeutics, Inc. | Purified cenicriviroc and purified intermediates for making cenicriviroc |
CN106248947A (zh) * | 2016-07-21 | 2016-12-21 | 中国人民解放军军事医学科学院基础医学研究所 | 一种哺乳动物高原脑水肿生物标志物及其应用 |
SG11201901438VA (en) | 2016-08-31 | 2019-03-28 | Tobira Therapeutics Inc | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
CA3041712A1 (en) | 2016-11-04 | 2018-05-11 | Children's Hospital Medical Center | Liver organoid compositions and methods of making and using same |
SG10202105768WA (en) | 2016-12-05 | 2021-06-29 | Childrens Hospital Med Ct | Colonic organoids and methods of making and using same |
EA201991990A1 (ru) * | 2017-02-24 | 2020-04-07 | Женфит | Фармацевтические композиции для комбинированной терапии |
JP7263659B2 (ja) * | 2018-02-02 | 2023-04-25 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用 |
GB201804922D0 (en) * | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
WO2021133811A1 (en) * | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
EP4192495A1 (en) * | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU778173B2 (en) * | 1999-12-08 | 2004-11-18 | Teijin Limited | Cycloamine CCR5 receptor antagonists |
AR034985A1 (es) | 2001-08-08 | 2004-03-24 | Takeda Chemical Industries Ltd | Compuesto biciclico; produccion y uso del mismo |
CH696628A5 (de) * | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
EP1825866A4 (en) | 2004-12-03 | 2008-03-12 | Takeda Pharmaceutical | SOLID PREPARATION |
AU2006252718B2 (en) * | 2005-05-31 | 2010-04-15 | Novartis Ag | Treatment of liver diseases in which iron plays a role in pathogenesis |
CN101511800B (zh) * | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
US20080194575A1 (en) * | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
EA200970350A1 (ru) * | 2006-10-05 | 2009-12-30 | Сентокор Орто Байотек, Инк. | Антагонисты ccr2 для лечения фиброза |
RU2337365C1 (ru) * | 2006-12-12 | 2008-10-27 | Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) | Способ дифференциальной диагностики алкогольного и неалкогольного стеатогепатита |
RU2435593C2 (ru) * | 2009-07-21 | 2011-12-10 | Лев Давидович Раснецов | Фармацевтическая композиция для лечения сахарного диабета 2 типа и лекарственное средство на его основе |
KR20160013068A (ko) * | 2013-05-15 | 2016-02-03 | 토비라 쎄라퓨틱스, 인크. | 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 |
-
2015
- 2015-03-20 CA CA2941411A patent/CA2941411A1/en not_active Abandoned
- 2015-03-20 US US15/127,720 patent/US20170239262A1/en not_active Abandoned
- 2015-03-20 KR KR1020167028892A patent/KR20160132489A/ko not_active Application Discontinuation
- 2015-03-20 RU RU2016141281A patent/RU2724339C2/ru active
- 2015-03-20 CN CN201580021915.3A patent/CN106488769A/zh active Pending
- 2015-03-20 SG SG11201607859SA patent/SG11201607859SA/en unknown
- 2015-03-20 WO PCT/US2015/021828 patent/WO2015143367A2/en active Application Filing
- 2015-03-20 EP EP15765327.0A patent/EP3119401A4/en not_active Withdrawn
- 2015-03-20 MX MX2016012262A patent/MX2016012262A/es unknown
- 2015-03-20 SG SG10201808104RA patent/SG10201808104RA/en unknown
- 2015-03-20 MA MA039748A patent/MA39748A/fr unknown
- 2015-03-20 EP EP21158407.3A patent/EP3922246A1/en not_active Withdrawn
- 2015-03-20 JP JP2017501137A patent/JP6556825B2/ja not_active Expired - Fee Related
- 2015-03-20 BR BR112016021682-2A patent/BR112016021682A2/pt not_active Application Discontinuation
- 2015-03-20 RU RU2020119611A patent/RU2020119611A/ru unknown
- 2015-03-20 AU AU2015230986A patent/AU2015230986A1/en not_active Abandoned
-
2016
- 2016-08-28 IL IL247515A patent/IL247515A0/en unknown
- 2016-09-21 CL CL2016002372A patent/CL2016002372A1/es unknown
-
2017
- 2017-06-14 HK HK17105882.1A patent/HK1232147A1/zh unknown
-
2018
- 2018-10-01 US US16/148,749 patent/US20190099429A1/en not_active Abandoned
-
2020
- 2020-04-30 US US16/863,711 patent/US20200368247A1/en not_active Abandoned
- 2020-06-11 AU AU2020203867A patent/AU2020203867A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2016012262A (es) | 2017-01-06 |
WO2015143367A2 (en) | 2015-09-24 |
JP6556825B2 (ja) | 2019-08-07 |
RU2724339C2 (ru) | 2020-06-23 |
US20170239262A1 (en) | 2017-08-24 |
RU2016141281A (ru) | 2018-04-23 |
AU2020203867A1 (en) | 2020-07-02 |
EP3119401A2 (en) | 2017-01-25 |
EP3119401A4 (en) | 2017-12-13 |
RU2016141281A3 (zh) | 2018-10-26 |
CA2941411A1 (en) | 2015-09-24 |
CL2016002372A1 (es) | 2017-02-10 |
MA39748A (fr) | 2021-04-21 |
CN106488769A (zh) | 2017-03-08 |
US20190099429A1 (en) | 2019-04-04 |
KR20160132489A (ko) | 2016-11-18 |
BR112016021682A2 (pt) | 2018-06-26 |
IL247515A0 (en) | 2016-11-30 |
US20200368247A1 (en) | 2020-11-26 |
SG10201808104RA (en) | 2018-10-30 |
RU2020119611A (ru) | 2020-06-29 |
EP3922246A1 (en) | 2021-12-15 |
AU2015230986A1 (en) | 2016-10-13 |
JP2017509704A (ja) | 2017-04-06 |
SG11201607859SA (en) | 2016-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1232147A1 (zh) | 用於治療纖維化的賽尼克韋羅 | |
HRP20181692T1 (hr) | Liječenje fibroze | |
IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
IL248856A0 (en) | New treatment | |
HK1244482A1 (zh) | 用於治療神經母細胞瘤的組合 | |
HK1247558A1 (zh) | 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化 | |
HK1244692A1 (zh) | 治療纖維化的方法 | |
HK1210590A1 (zh) | 高膽固醇血症的治療方法 | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
GB201411027D0 (en) | Treatment | |
IL266530A (en) | Treatment for fibrosis | |
GB201407806D0 (en) | Treatment of fibrosis | |
AU2014904206A0 (en) | Treatment of fibrosis | |
GB201417719D0 (en) | New treatment | |
GB201408384D0 (en) | New treatment | |
GB201413317D0 (en) | Atheroscierosis treatment | |
GB201412410D0 (en) | Treatment | |
GB201412411D0 (en) | Treatment | |
GB201402924D0 (en) | The theory of instantransmission | |
GB201400238D0 (en) | Treatment | |
GB201400241D0 (en) | Treatment | |
GB201400240D0 (en) | Treatment | |
GB201400239D0 (en) | Treatment | |
GB201400235D0 (en) | Treatment |